Secretin (ChiRhoStim): FDA-approved GI peptide research overview

Secretin is a 27-amino acid peptide hormone produced by S-cells in the proximal small intestine in response to duodenal acidification. It was one of the first hormones ever identified — discovered by Bayliss and Starling in 1902 — and plays a central role in regulating pancreatic bicarbonate secretion, bile flow, and gastric acid inhibition. In clinical medicine, secretin has a narrow but well-defined FDA-approved role as a diagnostic agent: it is used to stimulate pancreatic secretions for functional testing and to facilitate endoscopic retrograde cholangiopancreatography (ERCP). The peptide gained brief and intense public attention in the 1990s when anecdotal reports suggested it might improve symptoms of autism. A rigorous double-blind clinical trial published in 1999 in the New England Journal of Medicine found no such benefit, a finding confirmed by subsequent studies. This guide examines the science honestly across all three areas.

What is secretin?

Secretin is a linear 27-amino acid polypeptide (His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2) with a molecular weight of approximately 3,056 Da. It belongs to the secretin-glucagon superfamily of peptide hormones alongside glucagon, GLP-1, GLP-2, GIP, VIP, and PACAP. Secretin signals through the secretin receptor (SCTR), a class B G-protein-coupled receptor coupled to adenylate cyclase, driving intracellular cAMP production. The commercial injectable form ChiRhoStim is synthetic human secretin manufactured by ChiRhoClin, Inc. and received initial FDA approval in 2004. Porcine secretin (Ferring) was previously available and approved in 1981 for diagnostic use; ChiRhoStim provides a human-sequence alternative that eliminates the risk of porcine hypersensitivity reactions.

Physiologically, secretin is released from duodenal S-cells when luminal pH drops below approximately 4.5, stimulating the pancreatic ductal cells to secrete bicarbonate-rich fluid that neutralizes gastric acid in the duodenum. It also augments cholecystokinin (CCK)-stimulated enzyme secretion from acinar cells, promotes bile flow, and inhibits gastric acid secretion and gastric motility. These actions make it an ideal probe for assessing pancreatic exocrine reserve in diagnostic settings.

Mechanism of action

Secretin binds to the secretin receptor (SCTR), a class B (secretin family) GPCR expressed on pancreatic ductal epithelial cells, biliary epithelium, gastric parietal cells, hepatocytes, smooth muscle, and the central nervous system. Receptor activation triggers Gs-mediated adenylate cyclase stimulation, raising intracellular cAMP, which activates protein kinase A (PKA) and opens the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel on the apical membrane of ductal cells. The net effect is secretion of bicarbonate-rich, enzyme-poor fluid from the pancreatic ducts — the primary physiological response measured in diagnostic pancreatic function testing. In biliary epithelium (cholangiocytes), the same cAMP pathway drives bile secretion and ductular fluid output, relevant to its use in secretin-enhanced MRCP imaging.

What the research shows

Secretin's FDA-approved diagnostic utility is well-established and not controversial. In pancreatic function testing, intravenous administration of 0.2 mcg/kg synthetic human secretin stimulates the pancreas to secrete bicarbonate-rich fluid, which is collected from the duodenum via tube or endoscopy over 60 minutes; peak bicarbonate concentration below 80 mEq/L indicates exocrine pancreatic insufficiency with high sensitivity. This is the gold-standard secretin stimulation test. For ERCP, secretin relaxes the sphincter of Oddi and increases pancreatic duct flow, facilitating cannulation and visualization. In secretin-enhanced MRCP (a non-endoscopic imaging technique), the drug improves visualization of pancreatic duct anatomy and is used to detect strictures and assess ductal reserve.

The autism episode is an important part of secretin's history and merits careful treatment. In 1998, a case report described three children with autism who underwent secretin infusion during GI evaluation and whose parents subsequently reported dramatic behavioral improvements. The report received extensive media coverage and generated intense demand; within months, thousands of children with autism spectrum disorders had received off-label secretin infusions. In response, the National Institute of Child Health and Human Development funded a rigorous trial. Sandler et al. conducted a double-blind, placebo-controlled, randomized trial of a single intravenous dose of synthetic human secretin in 60 children aged 3–14 years with autism or pervasive developmental disorder. The results, published in the New England Journal of Medicine on December 9, 1999 (PMID 10588965), showed no benefit of secretin over placebo on any behavioral measure. Subsequent trials confirmed the null finding. The Cochrane Database review (Williams et al., 2012) evaluated 16 randomized trials enrolling 900 children and found no evidence of benefit for secretin in autism spectrum disorders.

Despite the unambiguous clinical trial evidence, secretin continues to circulate in some alternative-medicine communities as a purported autism treatment. This is a cautionary example of how anecdotal case reports — even earnestly reported by parents — can diverge sharply from randomized controlled trial results, possibly due to regression to the mean, placebo response in observers, or natural symptom variation. There is no scientific basis for using secretin to treat autism spectrum disorder, and it is not endorsed for this purpose in any major clinical guideline.

Pharmacokinetics

Synthetic human secretin (ChiRhoStim) is administered intravenously for diagnostic purposes. Following IV administration, peak plasma concentrations are achieved within 1–2 minutes; the peptide is rapidly cleared with a plasma half-life of approximately 45 minutes. Distribution is into plasma and interstitial fluid; volume of distribution is not precisely characterized for the synthetic human form. Metabolism occurs by proteolytic degradation, primarily in the kidneys and blood. The short half-life is appropriate for its use as a diagnostic probe, where a brief, reproducible secretory stimulus is desired. Secretin is not orally bioavailable and cannot be administered by subcutaneous injection for diagnostic purposes given the need for precise IV delivery and controlled timing of duodenal sampling.

Approved indications and dose ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

ChiRhoStim (synthetic human secretin) is FDA-approved for: (1) stimulation of pancreatic secretions to aid in diagnosis of exocrine pancreatic dysfunction; (2) stimulation of pancreatic secretions to aid in obtaining a cytologic specimen during ERCP; and (3) stimulation of gastrin secretion to aid in diagnosis of Zollinger-Ellison syndrome. The approved intravenous dose is 0.2 mcg/kg administered over 1 minute. ChiRhoStim is supplied as a lyophilized powder in vials for reconstitution. The DailyMed prescribing information (NDA 021256) provides full dosing and procedural guidance.

Storage and handling

ChiRhoStim should be stored at room temperature (up to 25 °C) prior to reconstitution; the product has a 5-year shelf life under approved storage conditions per a 2017 FDA-approved labeling update. Reconstituted solution should be used immediately. The product should be protected from light and excessive heat. For research-grade secretin peptide, lyophilized material should be stored at −20 °C in a desiccated, sealed vial; reconstituted solutions should be used within 24 hours or kept at 2–8 °C for a maximum of 7 days. As a 27-amino acid linear peptide without protective modifications, secretin is susceptible to proteolytic degradation in solution.

What secretin is NOT

Secretin is not a treatment for autism spectrum disorder. The clinical trial evidence — including a landmark double-blind NEJM trial and a Cochrane review of 16 randomized trials — is unambiguous: secretin provides no benefit over placebo on behavioral outcomes in autism or pervasive developmental disorder. Despite continuing claims in alternative-medicine circles, there is no scientific basis for this use. Secretin is also not a peptide supplement in the sense used by the research-peptide market; it is available only as an FDA-approved injectable diagnostic agent and is not sold for self-administration. It should not be confused with other GI peptides such as cholecystokinin (CCK), glucagon, GIP, or GLP-1, which act through distinct receptors for different physiological purposes.

References

Key sources include the pivotal autism trial (Sandler et al., NEJM 1999; PMID 10588965), the ChiRhoStim DailyMed prescribing information, the ChiRhoStim FDA label (accessdata.fda.gov NDA 021256), the Cochrane review on secretin and autism (Williams et al., 2012), and the secretin-enhanced MRCP review published in AJR (ajronline.org doi 10.2214/AJR.20.24857).